BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 38350611)

  • 21. Evolution of myeloid leukemia in children with Down syndrome.
    Saida S
    Int J Hematol; 2016 Apr; 103(4):365-72. PubMed ID: 26910243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A sensitive and inexpensive high-resolution melting-based testing algorithm for diagnosis of transient abnormal myelopoiesis and myeloid leukemia of Down syndrome.
    Camargo R; de Castro Moreira Dos Santos A; Cândido Guido B; Lemos Mendanha Cavalcante L; Silva Dias AC; Mendonça de Pontes R; Magalhães Furtado F; Feitosa Salviano C; Tiziani V; Martins Córdoba JC; Quezado Magalhães IM
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29866. PubMed ID: 35731576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-155-5p Plays a Critical Role in Transient Leukemia of Down Syndrome by Targeting Tumor Necrosis Factor Receptor Superfamily Members.
    Sas V; Pasca S; Jurj A; Pop L; Muramatsu H; Ono H; Dima D; Teodorescu P; Iluta S; Turcas C; Onaciu A; Munteanu R; Zimta AA; Blag C; Popa G; von Gamm EDA; Arghirescu S; Serban M; Man S; Marian M; Petrushev B; Berce C; Colita A; Zdrenghea M; Kojima S; Gulei D; Takahashi Y; Tomuleasa C
    Cell Physiol Biochem; 2020 Oct; 54(5):994-1012. PubMed ID: 33006449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Abnormal hematopoiesis in Down syndrome].
    Ito E
    Rinsho Ketsueki; 2014 Oct; 55(10):1738-47. PubMed ID: 25297735
    [No Abstract]   [Full Text] [Related]  

  • 25. Distinct GATA1 Point Mutations in Monozygotic Twins With Down Syndrome and Transient Abnormal Myelopoiesis From a Triplet Pregnancy: A Case Report and Review of Literature.
    Yin L; Lovell MA; Wilson ML; Wei Q; Liang X
    Am J Clin Pathol; 2016 Dec; 146(6):753-759. PubMed ID: 28028114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia.
    Palma CA; Al Sheikha D; Lim TK; Bryant A; Vu TT; Jayaswal V; Ma DD
    Mol Cancer; 2014 Apr; 13():79. PubMed ID: 24708856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits.
    Brioschi M; Fischer J; Cairoli R; Rossetti S; Pezzetti L; Nichelatti M; Turrini M; Corlazzoli F; Scarpati B; Morra E; Sacchi N; Beghini A
    Neoplasia; 2010 Nov; 12(11):866-76. PubMed ID: 21076613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing therapy for myeloid disorders of Down syndrome.
    Webb DK
    Br J Haematol; 2005 Oct; 131(1):3-7. PubMed ID: 16173956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematological disorders in children with Down syndrome.
    Triarico S; Trombatore G; Capozza MA; Romano A; Mastrangelo S; Attinà G; Maurizi P; Ruggiero A
    Expert Rev Hematol; 2022 Feb; 15(2):127-135. PubMed ID: 35184659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mapping the cellular origin and early evolution of leukemia in Down syndrome.
    Wagenblast E; Araújo J; Gan OI; Cutting SK; Murison A; Krivdova G; Azkanaz M; McLeod JL; Smith SA; Gratton BA; Marhon SA; Gabra M; Medeiros JJF; Manteghi S; Chen J; Chan-Seng-Yue M; Garcia-Prat L; Salmena L; De Carvalho DD; Abelson S; Abdelhaleem M; Chong K; Roifman M; Shannon P; Wang JCY; Hitzler JK; Chitayat D; Dick JE; Lechman ER
    Science; 2021 Jul; 373(6551):. PubMed ID: 34244384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome.
    Roy A; Roberts I; Vyas P
    Semin Fetal Neonatal Med; 2012 Aug; 17(4):196-201. PubMed ID: 22421527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-362-5p promotes the malignancy of chronic myelocytic leukaemia via down-regulation of GADD45α.
    Yang P; Ni F; Deng RQ; Qiang G; Zhao H; Yang MZ; Wang XY; Xu YZ; Chen L; Chen DL; Chen ZJ; Kan LX; Wang SY
    Mol Cancer; 2015 Nov; 14():190. PubMed ID: 26545365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia.
    Kanezaki R; Toki T; Terui K; Xu G; Wang R; Shimada A; Hama A; Kanegane H; Kawakami K; Endo M; Hasegawa D; Kogawa K; Adachi S; Ikeda Y; Iwamoto S; Taga T; Kosaka Y; Kojima S; Hayashi Y; Ito E
    Blood; 2010 Nov; 116(22):4631-8. PubMed ID: 20729467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prominent megakaryocytic dysplasia after regression of transient abnormal myelopoiesis associated with GATA-1 mutation.
    Anoop P; Atra A
    J Pediatr Hematol Oncol; 2012 Nov; 34(8):640. PubMed ID: 23007419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome.
    Xu G; Nagano M; Kanezaki R; Toki T; Hayashi Y; Taketani T; Taki T; Mitui T; Koike K; Kato K; Imaizumi M; Sekine I; Ikeda Y; Hanada R; Sako M; Kudo K; Kojima S; Ohneda O; Yamamoto M; Ito E
    Blood; 2003 Oct; 102(8):2960-8. PubMed ID: 12816863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1.
    Morenos L; Chatterton Z; Ng JL; Halemba MS; Parkinson-Bates M; Mechinaud F; Elwood N; Saffery R; Wong NC
    Mol Cancer; 2014 May; 13():123. PubMed ID: 24885794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mirror syndrome associated with fetal transient abnormal myelopoiesis in Down syndrome.
    Kobayashi Y; Miyoshi T; Matsuyama TA; Miyauchi J; Miyashita T; Ishibashi-Ueda H; Yoshimatsu J
    Pathol Int; 2015 Aug; 65(8):443-5. PubMed ID: 25808295
    [No Abstract]   [Full Text] [Related]  

  • 38. The paradox of Myeloid Leukemia associated with Down syndrome.
    Gupte A; Al-Antary ET; Edwards H; Ravindranath Y; Ge Y; Taub JW
    Biochem Pharmacol; 2022 Jul; 201():115046. PubMed ID: 35483417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia.
    Bi L; Zhou B; Li H; He L; Wang C; Wang Z; Zhu L; Chen M; Gao S
    BMC Cancer; 2018 Feb; 18(1):182. PubMed ID: 29439669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia.
    Jiang X; Hu C; Arnovitz S; Bugno J; Yu M; Zuo Z; Chen P; Huang H; Ulrich B; Gurbuxani S; Weng H; Strong J; Wang Y; Li Y; Salat J; Li S; Elkahloun AG; Yang Y; Neilly MB; Larson RA; Le Beau MM; Herold T; Bohlander SK; Liu PP; Zhang J; Li Z; He C; Jin J; Hong S; Chen J
    Nat Commun; 2016 Apr; 7():11452. PubMed ID: 27116251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.